NCE-1 Intelligence & Market Opportunity

Mounjaro

Tirzepatide

Antidiabetic

Subcutaneous Solution

Approval Date

13-May-22

NCE-1 Date

13-May-26

NCE Date

13-May-27

Commercial snapshot

Market performance & projections

Revenue ($M)

22965

CAGR (%)

0.1962

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

35002

2027

39798

2028

43616

2029

47026

2030

49861

2031

52602

2032

54903

Molecule profile

Details & specifications

Molecule

Tirzepatide

Innovator

ELI LILLY AND COMPANY

Dosage Form

Subcutaneous Solution

Strength

60 mg/2.4 mL (25 mg/mL), 40 mg/2.4 mL (16.7 mg/mL), 5 mg/0.5 mL (5 mg/0.5 mL), 20 mg/2.4 mL (8.33 mg/mL), 15 mg/0.5 mL (15 mg/0.5 mL), 10 mg/0.5 mL (10 mg/0.5 mL), 10 mg/2.4 mL (4.17 mg/mL), 50 mg/2.4 mL (20.8 mg/mL), 7.5 mg/0.5 mL (7.5 mg/0.5 mL), 30 mg/2.4 mL (12.5 mg/mL), 2.5 mg/0.5 mL (2.5 mg/0.5 mL), 12.5 mg/0.5 mL (12.5 mg/0.5 mL)

Therapeutic Category

Antidiabetic

Usage

To improve blood sugar control in diabetes, in addition to diet and exercise

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.